ONE YEARS EXPERIENCE WITH RECOMBINANT ERYTHROPOIETIN IN CHILDREN UNDERGOING CONTINUOUS AMBULATORY OR CYCLING PERITONEAL-DIALYSIS

被引：25

作者：

OFFNER, G

HOYER, PF

LATTA, K

WINKLER, L

BRODEHL, J

SCIGALLA, P

机构：

[1] Department of Paediatric Nephrology and Metabolic Disorders, Childrens Hospital Medical School, Hannover

[2] Boehringer Mannheim GmbH, Mannheim

来源：

PEDIATRIC NEPHROLOGY | 1990年 / 4卷 / 05期

关键词：

RECOMBINANT HUMAN ERYTHROPOIETIN; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTINUOUS CYCLING PERITONEAL DIALYSIS; RENAL ANEMIA;

D O I：

10.1007/BF00869830

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Fourteen patients (aged 5.9-22.1 years) undergoing continuous ambulatory or cycling peritoneal dialysis were treated with recombinant human erythropoietin (rhEPO), which was given intravenously once a week at a dosage of 300 units/kg. The mean haematocrit level increased from 18.5% to 27.5% and the reticulocyte count from 19 parts per thousand to 62 parts per thousand within 1 month. After an average time of 3.1 months rhEPO dosage could be adjusted to 100 units/kg per week to keep the haematocrit level at 30%. Only 1 patient had an exacerbation of hypertension, which required a dosage reduction; other side-effects were not noted.

引用

页码：498 / 500

页数：3

共 12 条

[1]

Offner G., Aschendorff C., Hoyer P.F., Krohn H.P., Ehrich J.H.H., Pichlmayr R., Brodehl J., End-stage renal failure: 14 years experience of dialysis and renal transplantation, Arch Dis Child, 63, pp. 120-126, (1988)

[2]

Zappacosta A.R., Caro J., Erslev A., Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis, Am J Med, 72, pp. 53-57, (1982)

[3]

DePaene M.B.J., Schelstraete K.H.G., Rengoir S.M.G., Lameire N.H., Influence of continuous ambulatory peritoneal dialysis on the anemia of endstage renal disease, Kidney International, 23, pp. 744-748, (1983)

[4]

Jakobs K., Shoemaker C., Rudersdorf R., Neill S.D., Kaufman R.J., Mufson A., Seehra J., Jones S.S., Hewick R., Fritsch E.F., Kawakita M., Shimizu T., Miyake T., Isolation and characterization of genomic and cDNA clones of human erythropoietin, Nature, 313, pp. 806-810, (1985)

[5]

Scigalla P., Bonzel K.E., Bulla M., Burghard R., Dippel J., Geisert J., Leumann E., von Lilien T., De Mueller, Offner G., Pistor K., Zoellner K., Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease, Contrib Nephrol, 76, pp. 227-241, (1989)

[6]

Kurtz A., Eckardt K.U., Bestimmungsmethoden für Erythropoietin, Nephron, 51, pp. 11-14, (1989)

[7]

MacDougall I.C., Coles G.A., Willia J.D., The pharmacokinetics of recombinant erythropoietin in CAPD patients (abstract), Dial Transplant, 17, (1988)

[8]

Eschbach J., The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin, Kidney Int, 35, pp. 134-148, (1989)

[9]

Mladenovic J., Eschbach J.W., Garcia J.F., Wahl P.W., Adaon J.W., Erythropoietin kinetics in normal and uremic sheep, J Lab Clin Med, 105, pp. 659-663, (1984)

[10]

Sinai-Trieman L., Salusky I.B., Fine R.N., Use of subcutaneous human erythropoietin in children undergoing continuous cycling peritoneal dialysis, J Pediatr, 114, pp. 550-554, (1989)

← 1 2 →